The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.

@article{Song2011TheEO,
  title={The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.},
  author={Ivy H. Song and Sherene S. Min and Julie Borland and Yu F Lou and Shuguang Chen and Parul Parag Patel and Toru Ishibashi and Stephen C. Piscitelli},
  journal={Journal of clinical pharmacology},
  year={2011},
  volume={51 2},
  pages={237-42}
}
S/GSK1349572 is an unboosted, once-daily integrase inhibitor with a novel resistance profile. As standard of care for patients infected with HIV is combination therapy, the potential interaction between S/GSK1349572 and ritonavir-boosted protease inhibitors was evaluated. In an open-label, repeat-dose, 2-period, 2-sequence crossover study in healthy participants, S/GSK1349572 was administered at 30 mg once daily for 5 days, followed by randomization to lopinavir/ritonavir 400/100 mg twice daily… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-9 of 9 references

The HIV integrase inhibitor elvitegravir has potent and durable activity in treatmentexperienced patients with active optimized background therapy

AR Zolopa, H Lampiris, G Blick
-1

Similar Papers

Loading similar papers…